Vygon opens Portuguese plant for chemotherapy devices

Ecouen, France's Vygon announced the completion of a €7 million ($8 million) 25,000 square meter in Paredes, Portugal to manufacture its drug delivering oncology devices. It intends to create more than 120 jobs in the area over the next five years.

Specifically, the facility will make the company's Qimono connectors for safe handling and administration of hazardous chemotherapy medications, according to a release.

It's described as a "pilot facility that will allow Vygon to move its new products from the design to the production stage." The plant can double its production facilities, and is expected to manufacture newly-launched products in the future, Vygon says, adding that it may decide to automate production at other sites, depending on the market for the new products.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

The company now has 4 manufacturing facilities in France, and 1 in Belgium, Germany, Portugal, the U.S., Columbia and Mauritius. European facilities account for 89% of its products by value.  

"This new facility forms an integral part of our Vygview 2022 vision and our industrial infrastructure, with the aim of improving our responsiveness between the product design and the automated production phases," said Stéphane Regnault, chairman of Vygon's management board, in a statement. "The new plant has an important role to play in Vygon Group's growth. It will improve our ability to meet our customers' needs. The Qimono range taps into a fast-growing market that will help drive the Group's organic growth over the next few years."

Vygon makes a range of single-use devices, including catheters, intravenous needles, tourniquets, venous filters and humidifying filters.

- read the release (PDF)

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.